Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations

PURPOSE: To evaluate the effectiveness and safety of gefitinib retreatment beyond disease progression in patients with advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations. METHODS: Data from patients with stage III/IV NSCLC were analyzed retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xuhong, Li, Xiaoqing, Tu, Lingli, Cai, Jin, Wei, Man, Wu, Zhongjun, Sun, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Retrospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550958/
https://www.ncbi.nlm.nih.gov/pubmed/33032475
http://dx.doi.org/10.1177/0300060520955030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550958/
https://www.ncbi.nlm.nih.gov/pubmed/33032475
http://dx.doi.org/10.1177/0300060520955030

Ejemplares similares